Adicet Webcast to Discuss Updated Data from Ongoing Phase 1 Lymphoma Trial

 Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that the Company will host a webcast presentation on Sunday, December 11, 2022 at 9:00 a.m. EST to discuss the most recent data-cut from its ongoing Phase 1 study evaluating the safety and tolerability of ADI-001 for the potential treatment of relapsed or refractory B-cell NHL.

The event will feature Sattva Neelapu, M.D., Professor in the Department of Lymphoma-Myeloma, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, alongside members of the Adicet management team.

Conference Call and Webcast Event

The live webcast of the presentation can be accessed by registering under "Presentations & Events" in the investors section of the Company’s website at https://www.adicetbio.com. Upon registration, all participants will receive a confirmation email with a unique passcode to provide access to the webcast event. To participate via telephone, please join by dialing 1-833-548-0276 (domestic) or 1-646-876-9923 (international) and referencing the conference ID 98173615816.

An archived replay will be available for 30 days following the presentation. The archived webcast will be available on the Company's website beginning approximately two hours after the event.

https://finance.yahoo.com/news/adicet-bio-host-investor-webcast-120000584.html

HTG Molecular Diagnostics Announces Next Event in RNA Profiling in Drug Discovery KOL

  HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced it will host its next HTG Therapeutics key opinion leader (KOL) webinar: “The Role of RNA Profiling in Drug Discovery and Analysis”, on Tuesday, December 13, 2022 at 11:00 am Eastern Standard Time.

This latest webinar features a presentation from KOL, Dr. Robert Spitale, PhD, from the University of California - Irvine, discussing the use of RNA profiling in the drug discovery process to better uncover mechanism of action and refine the drug screening processes.

Additionally, the HTG Therapeutics team will present results from the application of its transcriptome-informed drug discovery process. Specifically, differential regulation of the ferroptosis pathway by structurally similar compounds that target mTOR will be offered as an example of how RNA profiling can aid in understanding post-target engagement consequences and expand our understanding of the biological implications of compound treatment.

https://finance.yahoo.com/news/htg-molecular-diagnostics-announces-next-130100207.html

China Jo-Jo Drugstores rallies

 U.S.-listed shares of China Jo-Jo Drugstores Inc. (CJJD) rallied on Friday as the stores filled with customers buying cold medicines after COVID restrictions were eased, MarketWatch's Jaimy Lee reported The stock was up 22%. The company, which is based in Hangzhou, China, operates drugstores and an online pharmacy in China. It is also a wholesale distributor of pharmacy products and grows and sells herbs used in traditional Chinese medicine.

https://www.morningstar.com/news/marketwatch/20221209424/omicron-subvariants-are-now-dominant-in-the-us-as-covid-cases-tick-up-and-new-york-city-becomes-a-hot-spot

FDA staff reviewers flag safety concerns over Cytokinetics' heart drug

 U.S. Food and Drug Administration staff reviewers on Friday identified safety and efficacy concerns about Cytokinetics Inc's heart drug, according to briefing documents published on the agency's website.

The late-stage data raises concerns about the drug's dose-limiting risks of heart failure, the reviewers said, adding it is unclear if the study would be enough to provide evidence of the treatment's effectiveness.

A panel of the health regulator's outside experts is scheduled to discuss approval on Dec. 13, and a decision is expected by Feb. 28.

The draft questions for the upcoming meeting were in line with expectations and the advisory committee may want to see additional data or analyses before recommending approval, analysts said.

The company's experimental drug, omecamtiv mecarbil, aims to reduce the risk of heart-related death or the need for hospitalization or other urgent care.

"We believe a mixed or even negative advisory committee meeting outcome is positive for the stock," said Piper Sandler analyst Yasmeen Rahimi, adding this would allow Cytokinetics to re-allocate its resources to aficamten, which is being evaluated as a treatment for an inherited heart condition.

Omecamtiv works by activating cardiac myosin, a protein in heart muscle cells responsible for converting chemical energy into the mechanical force that drives cardiac contraction.

Shares of the California-based company rose nearly 8% before giving up nearly all the gains.

https://finance.yahoo.com/news/fda-staff-reviewers-flag-safety-143233742.html

Jazz upped to Buy from Neutral by Goldman

 Target to $190 from $192

https://finviz.com/quote.ashx?t=JAZZ&ty=c&ta=1&p=d

Tivic, Reliefband Terminate Acquisition Agreement

 Tivic Health Systems, Inc. ("Tivic") (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced that Tivic Health and Reliefband Technologies, LLC have, by mutual agreement, terminated the parties’ agreement for the acquisition of the Reliefband product line and related assets entered into on October 7, 2022. Information regarding the termination is contained in the company’s Current Report on Form 8-K filed with the SEC.

"The current capital market conditions are volatile and, after reviewing various financing alternatives, we believe proceeding with the acquisition is not in the best interest of our stakeholders at this time," said Jennifer Ernst, CEO of Tivic Health. "The relationship between Tivic Health and Reliefband management remains on good terms despite both teams’ disappointment in the outcome. We remain committed to our growth strategy and will continue to evaluate M&A, licensing, and partnership opportunities. Our focus in the near term will be to accelerate sales of ClearUP and expand our organic product pipeline."

https://finance.yahoo.com/news/tivic-health-reliefband-technologies-llc-133000611.html

Rallybio started at Overweight by JPMorgan

 Target $21

https://finviz.com/quote.ashx?t=RLYB&ty=c&ta=1&p=d